Mecapegfilgrastim(PEG-G-CSF) for Prophylaxis of Chemotherapy-induced Neutropenia in Patients With Lymphoma
Status:
Recruiting
Trial end date:
2023-03-20
Target enrollment:
Participant gender:
Summary
Neutropenia is one of the most frequent adverse effects of chemotherapy, and the main factor
to limit the dosage and the continuation of chemotherapy.A newly pegylated rhG-CSF was
independently developed by JIANGSU HENGRUI Medicine Co., Ltd, China. Phase 1a, 1b and phase 2
trials have shown that pegylated rhG-CSF has decreased renal clearance, increased plasma
half-life, and prolonged efficacy in compare with filgrastim.
This study is to evaluate efficacy and safety in chemotherapy-induced neutropenia of
once-per-cycle Mecapegfilgrastim Injection(PEG-G-CSF) and daily G-CSF in Patients with
lymphoma patients.
Phase:
Phase 2
Details
Lead Sponsor:
First Hospital of Jilin University The First Hospital of Jilin University